Last reviewed · How we verify
H. pylori eradication scheme A
At a glance
| Generic name | H. pylori eradication scheme A |
|---|---|
| Also known as | Concomitant bismuth-free A |
| Sponsor | Unidade Local de Saúde de Coimbra, EPE |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole (PHASE4)
- A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication (PHASE4)
- Helicobacter Pylori Eradication Therapy in Portugal (NA)
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection (PHASE4)
- Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- H. pylori eradication scheme A CI brief — competitive landscape report
- H. pylori eradication scheme A updates RSS · CI watch RSS
- Unidade Local de Saúde de Coimbra, EPE portfolio CI